GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing - Test2 - elhamkhani - TriplyDB

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

http://www.wikidata.org/entity/Q24536109

about

Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A)Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice Emerging preclinical pharmacological targets for Parkinson's disease Multifaceted role of β-arrestins in inflammation and disease Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?NAD+ as a signaling molecule modulating metabolism Niacin, an old drug with a new twist Nicotinic acid receptor agonists differentially activate downstream effectors Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine Niacin sensitivity and the arachidonic acid pathway in schizophrenia Niacin in pharmacological doses alters microRNA expression in skeletal muscle of obese Zucker rats.A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Nicotinic acid activates the capsaicin receptor TRPV1: Potential mechanism for cutaneous flushing.Nicotinic acid receptor abnormalities in human skin cancer: implications for a role in epidermal differentiation.Internalization of the human nicotinic acid receptor GPR109A is regulated by G(i), GRK2, and arrestin3.Seeing red: flushing out instigators of niacin-associated skin toxicity.Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT Future of GPR109A agonists in the treatment of dyslipidaemia.Niacin: the evidence, clinical use, and future directions.Role of prostaglandin D2 and the autonomic nervous system in niacin-induced flushing.Nicotinic acid modulates intracellular calcium concentration and disassembles the cytoskeleton.Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages.The flavonoid luteolin inhibits niacin-induced flush Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans.Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters High dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice.Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS.Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.Biological roles and therapeutic potential of hydroxy-carboxylic Acid receptors.1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway.Activated human hydroxy-carboxylic acid receptor-3 signals to MAP kinase cascades via the PLC-dependent PKC and MMP-mediated EGFR pathways.A randomized pilot study on the effect of niacin on pulmonary arterial pressure.Aspirin in dermatology: Revisited.Identification and characterization of distinct C-terminal domains of the human hydroxycarboxylic acid receptor-2 that are essential for receptor export, constitutive activity, desensitization, and internalization.

P2860

Q24297428-15175445-C12B-4ECB-9F6C-DD8A07122D5A Q24536167-212B12EA-5B5F-4B4E-A414-064D6C13E5AA Q24594113-70AB2EF4-F4C5-4492-8BB0-329421F77C7F Q24600864-7FA931DC-2374-413B-A75A-E091C5293873 Q24654027-0A809452-3300-4787-8A6E-3D1155401D2B Q26764724-65DB4D05-12BA-4138-AF5F-A74884B445EF Q26785883-52D18478-2B35-4016-949C-687A015674AD Q26864685-5FEF15F0-8041-46F6-B609-5986A4B5BD80 Q26995735-E45273FE-5BF1-420A-B3A0-490BA84534EC Q27002774-53BCE95B-2919-4B37-9AB8-5D9AA5831FF6 Q28298974-06569194-DD72-4296-85CD-C257516AA492 Q28395286-0B22BDE1-48D2-4568-8D75-8DDE1D3F8951 Q33563595-BBA5ABF8-CE08-4808-A75F-50AB7E36D321 Q33646129-C3B057E8-B2BF-496C-A89D-558E0D5AFECC Q33765072-0BBE23C4-36F2-49D5-92AC-38CCEBE03F1C Q33778078-04C61915-F462-466A-8B09-3829AC80C295 Q33927010-6396A17F-B992-4299-8A7B-19422484D6FA Q33991193-A5A69736-D806-4B9B-A93F-CFE519E03F33 Q34028776-5B5061B6-37D3-4160-83E9-45E54FC7A1AC Q34029082-64D0BBE4-A34A-4C0C-BEEB-9E6AE90AD331 Q34171831-52C289FC-E665-4C9E-BA40-84C328574BCF Q34228636-5FC4AC1B-373E-413D-A34F-0332A5C6133F Q34315242-D30D0F4A-0EC1-4A87-86A7-1F197D1B1824 Q34487985-5130E102-B849-490B-BD8B-AA074B0C208D Q34565228-259442B4-D8E9-493C-B53E-BAA44016AAEB Q34587640-C188086E-7D94-47CF-994C-D769AE21FD33 Q34597967-85DFE5F4-2544-4B5A-BC76-D0C9665ED6C8 Q35220552-FCF9676E-DFE1-4A96-995A-FF8F9C6CBF3E Q35440499-29B14957-61FB-4C48-BE6B-F0E176EAE573 Q35575144-661D8BA7-C69E-4BCE-BFCE-43D47AB1F3DA Q35608570-8D7D3AC0-D11C-4B18-852C-A89D8B748D69 Q35805959-E7FDB584-2457-40EA-8B29-A3E352A1C42E Q35856171-A823F9F3-A9E8-4794-99B5-DB5E90562226 Q35895434-09002DD3-2E47-4E8A-AB02-987EDE166036 Q35971823-E68ED25C-5803-4EC0-80DF-BE6BB9BFDC19 Q35995199-B7423FF7-654E-41DA-BDD7-734F1C5B7B1D Q36110572-1CA7B8AC-C841-4A31-8655-F309DE2F6729 Q36304121-9917B24E-138A-42E8-82C7-6126B5B030C6 Q36409789-9E9BF55B-F1F6-4867-8922-213BD9FBDEA2 Q36412846-6BFF4D9A-EB3D-46EB-BD40-EF5BFCC6DA89

P2860

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

http://www.wikidata.org/entity/Q24536109

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

@ast

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

@en

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

@nl

type

label

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

@ast

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

@en

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

@nl

prefLabel

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

@ast

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

@en

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

@nl

P1433

Q24536109-6C1D4B9A-4B11-4F00-8868-2320BB05D257

P1476

Q24536109-4E841B52-93F5-4954-A5AA-BB0F6EA227AD

P2093

Q24536109-3CBED3D7-6681-40D7-ACBF-E98A6209CACF

Q24536109-418789CD-C7BA-429D-908A-B43D6067C8CB

Q24536109-46015B26-0590-4919-8D87-13E19847121D

Q24536109-B0B600EA-6469-4D73-9007-FDBCC3E91C37

P2860

Q24536109-0C7ABEFA-B522-461F-A097-D0C535EDEFF1

Q24536109-0F05872A-78AD-40B2-9899-B56AAE0996E4

Q24536109-13326780-E114-4F3F-88B2-EBD103D1AD66

Q24536109-15C77841-19BC-488C-B5F6-5FE9B748CBB1

Q24536109-16432CC8-F1D5-472D-A74C-602448633954

Q24536109-1AC018AE-E1D3-4A7D-985F-D318C3475AD2

Q24536109-27777A10-44B5-4D19-BFC1-610D00258791

Q24536109-3205AC86-27DE-4751-BF81-DD50E3243767

Q24536109-348BA774-FE90-47F9-9E09-5064A3B61810

Q24536109-3D58D79A-70F0-4E2F-AF61-C2000CE9B87E

P304

Q24536109-E763250B-497A-4800-8918-6725F94F7602

P31

Q24536109-2380F9E6-9A86-4543-8568-DD01191EB121

P3181

Q24536109-4FBA945C-3F9B-482D-8117-22DC357C2C6C

P356

Q24536109-897AD829-DF45-4197-B9C0-D162F0FCA8D9

P407

Q24536109-43E5B587-E3A6-446D-B9AC-C623B42EE7B3

P433

Q24536109-4DDB2A88-B2A0-4AE1-8CFC-7D4B3E1041D4

P478

Q24536109-44FFC301-8B88-461A-BBB3-AD8C8E5E45FF

P50

Q24536109-14547FA2-E96E-4314-8393-1775EDE9D30E

Q24536109-4A650300-66D4-4A5A-BF1A-C81EF003AE7C

Q24536109-6B1B5B08-5D23-4C89-AD08-2E55EF7041F5

Q24536109-BFB2A1D2-9400-4DFC-934A-15BAD7C3A46A

Q24536109-F01A0C2D-6E76-4DD8-9B81-0205AFB3DD8F

P577

Q24536109-2708FF89-02BD-4B77-A7C0-354FAB8B5167

P5875

Q24536109-275A7FE1-07B9-451D-AB8B-3DB0C26C0336

P698

Q24536109-B7970396-1586-411B-B982-E93912DA93E9

P932

Q24536109-924868BE-4E73-4109-803C-442291EAE836

P3181

P356

P1433

Journal of Clinical Investigation

P1476

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

@en

P2093

Alexandra Moers

http://www.w3.org/2001/XMLSchema#string

Marie Catherine Suchánková

http://www.w3.org/2001/XMLSchema#string

Marion Csiky

http://www.w3.org/2001/XMLSchema#string

Rolf M Nüsing

http://www.w3.org/2001/XMLSchema#string

P2860

Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2)

Molecular identification of nicotinic acid receptor

Expression and molecular pharmacology of the mouse CRTH2 receptor

Molecular identification of high and low affinity receptors for nicotinic acid

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans

Regulation of phosphoinositide-specific phospholipase C

G13 is an essential mediator of platelet activation in hemostasis and thrombosis

The expanding superfamily of phospholipase A(2) enzymes: classification and characterization

P304

3634-3640

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1861667

http://www.w3.org/2001/XMLSchema#string

P356

10.1172/JCI23626

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Stefan Offermanns

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7445891

http://www.w3.org/2001/XMLSchema#string

P698

16322797

http://www.w3.org/2001/XMLSchema#string

P932

1297235

http://www.w3.org/2001/XMLSchema#string